No insider purchase over the last 90 days. The latest, by JOBSON CHARLES E, was filed 14 May 2026.
JOINT Corp is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 14 filings were filed, from 4 insiders.
Every open-market trade in the period is a purchase: 10 purchases worth €1.4M, from 1 insider, and not a single sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 major shareholder. At €932k, the purchase published on 14 May 2026 by Jobson Charles e is the largest of the period (0.79% of market cap).
Across the 5,814 companies tracked on its exchange, the median is 19 filings; at 14 filings, this issuer sits below that mark. Since 2021, the database holds 43 purchases and 14 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 54.9 m USD and net income of 2.9 m USD.
The last purchase on record was published on 14 May 2026, which is 157 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 104 declarations
JOINT Corp. (ticker: JYNT) is a U.S.-based company listed on the NASDAQ in the United States. It operates in the chiropractic care segment through The Joint Chiropractic® network, combining clinic operations, management services, and franchising. For French-speaking investors, the investment case is best understood as a retail healthcare model: a consumer-facing wellness and pain-relief offering built around convenience, transparent pricing, and a simplified patient experience. The company is headquartered in Scottsdale, Arizona, and its brand proposition centers on walk-in access, no insurance complexity, and a standardized care format that differentiates it from traditional chiropractic practices. ([ir.thejoint.com](https://ir.thejoint.com/company-information?utm_source=openai))
The modern company says it acquired its predecessor in March 2010, marking the start of its current growth phase. Since then, The Joint Corp. has expanded from a small base into a nationwide platform. In its SEC filings, the company reported 967 clinics in operation at December 31, 2024, along with additional franchise licenses sold but not yet developed. Company materials also state that the network spans 43 states, with more than 14 million patient visits annually. This scale matters because the business model becomes more attractive as the network density improves and brand recognition strengthens. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1612630/000161263025000033/jynt-20241231.htm?utm_source=openai))
From a competitive standpoint, JOINT Corp. appears to be the clear scale leader in U.S. chiropractic care. Management says the brand is roughly six times larger than its nearest chiropractic chain competitor, which underscores its leading position in a still-fragmented category. The core service offering includes chiropractic adjustments, ongoing wellness care, and related patient treatment plans delivered through a standardized clinic format. The company’s recurring membership model and no-appointment approach are intended to make care more affordable and more accessible, while supporting repeat visits and a broader consumer audience. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1612630/000162828025012702/jynt-20241231.htm?utm_source=openai))
Recent developments have been focused on strategic simplification and profitability improvement. In 2024, the company continued to push toward a “pure-play franchisor” structure, refranchising certain corporate clinics and reducing direct operating exposure. In early 2025, management said it had begun executing initiatives to strengthen the core business, reignite growth, and improve both clinic-level and company-level profitability. That messaging is important for investors, as it signals a transition from a growth-at-all-costs expansion model toward a more disciplined franchise-led operating structure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1612630/000162828025012702/jynt-20241231.htm?utm_source=openai))
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2025 | 54.9 m USD | 2.9 m USD | 0.19 USD | 10-K |
| Dec 2024 | 52.2 m USD | -5.8 m USD | -0.38 USD | 10-K |
| Dec 2023 | 117.7 m USD | -9.8 m USD | -0.65 USD | 10-K |
| Dec 2022 | 101.3 m USD | 626,705 USD | -0.38 USD | 10-K |
| Dec 2021 | 80.0 m USD | 7.6 m USD | 0.51 USD | 10-K/A |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.